Rigel Pharmaceuticals, Inc. (RIGL) News
Track canonical SquawkNews coverage tagged to RIGL, Rigel Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Rigel announces VEPPANU availability for ER+/HER2- ESR1-mutated breast cancer
Rigel (RIGL) says VEPPANU™ (vepdegestrant) is now available for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
EQUITY | Aug 13, 2026, 12:06 PM UTC
L
RIGL RIGL - Rigel Reports Second Quarter 2026 Financial Results
RIGL RIGL - Rigel Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 08:01 PM UTC